Abbott Laboratories ROE 2010-2025 | ABT
Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Abbott Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-03-31 | $13.50B | $49.06B | 30.59% |
| 2024-12-31 | $13.40B | $47.90B | 32.19% |
| 2024-09-30 | $5.77B | $40.03B | 14.65% |
| 2024-06-30 | $5.56B | $39.56B | 14.33% |
| 2024-03-31 | $5.63B | $39.04B | 14.72% |
| 2023-12-31 | $5.72B | $38.83B | 15.14% |
| 2023-09-30 | $5.16B | $37.69B | 13.84% |
| 2023-06-30 | $5.16B | $37.40B | 14.00% |
| 2023-03-31 | $5.80B | $37.23B | 15.82% |
| 2022-12-31 | $6.93B | $36.91B | 19.11% |
| 2022-09-30 | $7.89B | $35.88B | 21.88% |
| 2022-06-30 | $8.55B | $36.72B | 23.93% |
| 2022-03-31 | $7.73B | $35.63B | 22.02% |
| 2021-12-31 | $7.07B | $36.02B | 20.42% |
| 2021-09-30 | $7.24B | $34.64B | 21.39% |
| 2021-06-30 | $6.38B | $34.03B | 19.26% |
| 2021-03-31 | $5.72B | $33.79B | 17.72% |
| 2020-12-31 | $4.50B | $33.00B | 14.29% |
| 2020-09-30 | $3.38B | $31.60B | 10.90% |
| 2020-06-30 | $3.11B | $30.80B | 9.99% |
| 2020-03-31 | $3.58B | $30.43B | 11.39% |
| 2019-12-31 | $3.69B | $31.30B | 11.67% |
| 2019-09-30 | $3.29B | $32.02B | 10.47% |
| 2019-06-30 | $2.90B | $31.89B | 9.29% |
| 2019-03-31 | $2.62B | $31.13B | 8.49% |
| 2018-12-31 | $2.37B | $30.72B | 7.64% |
| 2018-09-30 | $0.89B | $30.90B | 2.85% |
| 2018-06-30 | $0.93B | $30.77B | 2.95% |
| 2018-03-31 | $0.48B | $31.60B | 1.50% |
| 2017-12-31 | $0.48B | $31.10B | 1.51% |
| 2017-09-30 | $2.10B | $32.22B | 7.23% |
| 2017-06-30 | $1.17B | $31.79B | 4.46% |
| 2017-03-31 | $1.50B | $31.55B | 6.40% |
| 2016-12-31 | $1.40B | $20.72B | 6.73% |
| 2016-09-30 | $1.37B | $20.90B | 6.53% |
| 2016-06-30 | $2.28B | $20.80B | 10.82% |
| 2016-03-31 | $2.45B | $20.84B | 11.31% |
| 2015-12-31 | $4.42B | $21.33B | 20.18% |
| 2015-09-30 | $4.56B | $21.22B | 20.74% |
| 2015-06-30 | $4.52B | $23.13B | 20.14% |
| 2015-03-31 | $4.20B | $21.99B | 18.60% |
| 2014-12-31 | $2.28B | $21.64B | 9.95% |
| 2014-09-30 | $1.97B | $22.99B | 8.25% |
| 2014-06-30 | $2.40B | $23.70B | 9.96% |
| 2014-03-31 | $2.41B | $23.49B | 10.14% |
| 2013-12-31 | $2.58B | $25.27B | 10.94% |
| 2013-09-30 | $3.04B | $23.79B | 12.70% |
| 2013-06-30 | $4.02B | $22.43B | 16.22% |
| 2013-03-31 | $5.27B | $22.68B | 20.82% |
| 2012-12-31 | $5.96B | $26.81B | 22.93% |
| 2012-09-30 | $6.53B | $27.10B | 25.67% |
| 2012-06-30 | $4.89B | $24.57B | 19.69% |
| 2012-03-31 | $5.11B | $25.54B | 20.18% |
| 2011-12-31 | $4.73B | $24.53B | 18.84% |
| 2011-09-30 | $4.55B | $24.69B | 18.45% |
| 2011-06-30 | $5.14B | $26.47B | 21.54% |
| 2011-03-31 | $4.49B | $24.72B | 20.18% |
| 2010-12-31 | $4.63B | $22.77B | 21.71% |
| 2010-09-30 | $4.73B | $21.48B | 22.06% |
| 2010-06-30 | $5.31B | $20.00B | 24.84% |
| 2010-03-31 | $5.31B | $21.01B | 24.84% |
| 2009-12-31 | $5.75B | $23.19B | 27.87% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $231.329B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $151.540B | 37.94 |
| Stryker (SYK) | United States | $146.015B | 30.53 |
| EssilorLuxottica (ESLOY) | France | $127.709B | 0.00 |
| Medtronic (MDT) | Ireland | $109.786B | 15.56 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.554B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.214B | 28.03 |
| ResMed (RMD) | United States | $36.648B | 27.53 |
| Agilent Technologies (A) | United States | $32.650B | 21.28 |
| GE HealthCare Technologies (GEHC) | United States | $32.569B | 15.46 |
| Terumo (TRUMY) | Japan | $26.857B | 34.88 |
| Insulet (PODD) | United States | $22.464B | 88.18 |
| Koninklijke Philips (PHG) | Netherlands | $21.600B | 15.53 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.095B | 11.62 |
| Baxter (BAX) | United States | $15.380B | 11.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.819B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.637B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.043B | 21.03 |
| Lantheus Holdings (LNTH) | United States | $5.509B | 13.90 |
| Prestige Consumer Healthcare (PBH) | United States | $4.190B | 18.72 |
| Perrigo (PRGO) | Ireland | $3.610B | 9.15 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.346B | 15.24 |
| ICU Medical (ICUI) | United States | $3.233B | 23.84 |
| Envista Holdings (NVST) | United States | $3.178B | 26.41 |
| GN Store Nord (GNNDY) | Denmark | $2.155B | 17.85 |
| QuidelOrtho (QDEL) | United States | $2.102B | 14.46 |
| LeMaitre Vascular (LMAT) | United States | $1.865B | 41.69 |
| AtriCure (ATRC) | United States | $1.729B | 0.00 |
| Acuren (TIC) | United States | $1.228B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.196B | 12.14 |
| Green Thumb Industries (GTBIF) | United States | $1.101B | 24.76 |
| Neogen (NEOG) | United States | $1.077B | 13.78 |
| BioLife Solutions (BLFS) | United States | $1.046B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.016B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.972B | 12.42 |
| InMode (INMD) | Israel | $0.931B | 9.38 |
| Evolus (EOLS) | United States | $0.632B | 0.00 |
| CeriBell (CBLL) | United States | $0.619B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.571B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.564B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.563B | 0.00 |
| Valneva SE (VALN) | France | $0.523B | 0.00 |
| Owens & Minor (OMI) | United States | $0.515B | 4.27 |
| Surmodics (SRDX) | United States | $0.429B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.412B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.340B | 12.52 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.313B | 55.70 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.275B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| Sanara MedTech (SMTI) | United States | $0.260B | 0.00 |
| ZimVie (ZIMV) | United States | $0.255B | 11.61 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.239B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.231B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.217B | 0.00 |
| Quanterix (QTRX) | United States | $0.217B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.205B | 0.00 |
| Brainsway (BWAY) | Israel | $0.198B | 52.30 |
| Omeros (OMER) | United States | $0.196B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.195B | 0.00 |
| Biote (BTMD) | United States | $0.194B | 5.45 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.80 |
| Organigram Global (OGI) | Canada | $0.179B | 0.00 |
| Exagen (XGN) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.136B | 16.72 |
| Vireo Growth (VREOF) | United States | $0.125B | 0.00 |
| Jin Medical (ZJYL) | China | $0.121B | 0.00 |
| Veru (VERU) | United States | $0.096B | 0.00 |
| MacroGenics (MGNX) | United States | $0.095B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.56 |
| TerrAscend (TSNDF) | Canada | $0.089B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Zynex (ZYXI) | United States | $0.065B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.045B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.02 |
| Nephros (NEPH) | United States | $0.035B | 47.43 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.021B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |